Interventional Radiology Imaging

How Should You Manage a Solitary 3-5 cm Hepatocellular Cancer in Cirrhosis?

·
How Should You Manage a Solitary 3-5 cm Hepatocellular Cancer in Cirrhosis?

A 64-year-old man with a history of cirrhosis due to non-alcoholic steatohepatitis (NASH) presents for follow-up. His routine six-month surveillance imaging, a multiphasic MRI, reveals a new 4.2 cm arterial-enhancing lesion with washout, diagnostic of hepatocellular carcinoma (HCC). He has no evidence of vascular invasion or extrahepatic disease. He is in your clinic to discuss the next steps, feeling well but anxious about the diagnosis. You are now faced with a critical decision point: what is the optimal management strategy for this intermediate-stage, solitary tumor? This article provides a clinical workflow for this exact scenario, guided by the American College of Radiology (ACR) Appropriateness Criteria. For this patient, liver transplantation is rated Usually appropriate and represents a primary curative-intent option.

Who Fits This Clinical Scenario for Intermediate-Stage HCC?

This guidance applies to a specific subset of patients: those with a solitary hepatocellular carcinoma measuring between 3 and 5 cm in the setting of known cirrhosis. The patient should have a performance status that makes them a potential candidate for curative-intent therapy, such as transplantation or surgical resection. This scenario typically corresponds to Barcelona Clinic Liver Cancer (BCLC) stage A or B, where locoregional or surgical therapies are the mainstay of treatment.

It is crucial to distinguish this presentation from clinically similar but distinct scenarios that require a different management approach. This workflow does not apply if:

  • The tumor is smaller than 3 cm. For these smaller lesions, percutaneous ablation often becomes a more prominent and highly effective curative-intent option, as achieving a complete ablative margin is more feasible.
  • The patient has multifocal disease or a tumor larger than 5 cm. This presentation often falls outside standard transplant criteria (like the Milan criteria) and may require locoregional therapies like transarterial chemoembolization (TACE) as a primary treatment or for downstaging, rather than immediate consideration for transplant.
  • There is evidence of major vascular invasion or extrahepatic disease. The presence of portal vein tumor thrombus or metastatic disease signifies advanced HCC (BCLC stage C), where systemic therapies are the standard of care and curative-intent locoregional treatments are generally not appropriate.

What Are the Key Considerations in This Management Decision?

For a solitary 3-5 cm HCC, the diagnosis is often established, and the “workup” shifts from identifying the lesion to determining the optimal therapeutic pathway. The decision hinges on a comprehensive evaluation of the tumor, the patient’s underlying liver function, and their overall health.

The primary consideration is curative versus palliative intent. A solitary tumor of this size is at a critical juncture; it is often amenable to treatments that can achieve a complete cure, but only if the patient is a suitable candidate. The goal is to select the therapy that offers the highest probability of long-term, disease-free survival.

A central part of the workup is assessing transplant candidacy. Liver transplantation is unique in that it treats both the cancer and the underlying disease—the cirrhotic liver, which is at high risk for developing new tumors. This evaluation involves calculating the Model for End-Stage Liver Disease (MELD) score, assessing the degree of portal hypertension, and a thorough review of medical comorbidities and psychosocial factors to ensure the patient can tolerate and benefit from the procedure.

Simultaneously, resection candidacy must be evaluated. While surgical resection can also be curative, it leaves the diseased liver behind, carrying a significant risk of HCC recurrence. Suitability for resection depends on well-preserved liver function (typically Child-Pugh class A), the absence of clinically significant portal hypertension, and an adequate future liver remnant (FLR) to prevent post-operative liver failure.

Finally, the role of locoregional “bridge” or definitive therapy is considered. For patients who are candidates for transplant but face a long wait time, therapies like TACE or transarterial radioembolization (TARE) can be used as a “bridge” to control the tumor and prevent dropout from the transplant list. For those who are not candidates for either transplant or resection, these therapies can serve as the primary, definitive treatment.

Why Is Liver Transplantation a Top Recommended Option for a 3-5 cm HCC?

The ACR panel on Interventional Radiology rates multiple therapies as Usually appropriate for a solitary 3-5 cm HCC in a cirrhotic patient, reflecting the complexity of this decision. However, liver transplantation holds a unique position as a top-tier recommendation because it offers the highest potential for a definitive cure.

The core rationale for transplantation is its ability to address both the existing cancer and the “field defect” of the cirrhotic liver. By replacing the entire organ, it eliminates the risk of developing new, metachronous HCCs, a major cause of late recurrence after surgical resection. For a patient with a single 3-5 cm tumor, no vascular invasion, and no extrahepatic disease, they typically fall within the widely accepted Milan criteria, making them an excellent candidate for transplant with favorable long-term outcomes.

Other therapies are also highly rated but serve different roles or have different risk-benefit profiles:

  • Surgical Liver Resection: Also rated Usually appropriate, this is a curative-intent option primarily for patients with very well-compensated cirrhosis (Child-Pugh A, no significant portal hypertension). The primary drawback compared to transplant is the high rate of tumor recurrence in the remaining liver, which can exceed 50% at 5 years.
  • Transarterial Chemoembolization (TACE) and Radioembolization (TARE): These are also Usually appropriate. They are indispensable tools, often used as a bridge to keep a tumor from growing while a patient awaits transplant. In patients who are not candidates for surgery or transplant, these catheter-based therapies can provide durable tumor control and are often the primary treatment modality.
  • Percutaneous Ablation: This is rated May be appropriate. While highly effective for tumors under 3 cm, its efficacy diminishes for tumors in the 3-5 cm range. Achieving a complete, margin-negative ablation becomes technically more difficult, leading to a higher risk of local tumor recurrence compared to resection or transplant.

The initial diagnostic and staging workup for this scenario relies heavily on high-quality cross-sectional imaging. Once you’ve decided on a management pathway that involves locoregional therapy or close surveillance, our protocol guide covers the essential imaging technique. For details on imaging technique, contrast phases, and reporting principles, see our guide: CT Triphasic Liver (HCC Protocol).

What’s Next After the Initial Management Decision? Downstream Workflow

The management of a 3-5 cm HCC is not a single event but the beginning of a long-term surveillance and treatment pathway. The next steps are dictated by the chosen therapy and the patient’s response.

  • If the patient is a transplant candidate: The next step is formal evaluation at a transplant center. While on the waiting list, the patient will undergo regular follow-up imaging (typically every 3 months) to monitor for tumor progression. If the tumor grows, “bridge” therapy with TACE or TARE is often initiated to maintain their eligibility for transplant.
  • If the patient undergoes surgical resection: Post-operative surveillance imaging is critical to detect recurrence. This typically involves multiphasic CT or MRI every 3-6 months for the first few years. If a new intrahepatic tumor appears, the patient may then be considered for salvage transplantation or locoregional therapies.
  • If locoregional therapy (TACE/TARE/Ablation) is the definitive treatment: The immediate next step is post-procedure imaging, usually 1-3 months later, to assess treatment response (e.g., using mRECIST criteria). If there is residual or recurrent tumor, repeat locoregional therapy may be performed. If the disease progresses beyond what can be controlled locally, the patient may transition to a different ACR variant, such as management of multifocal disease or disease with vascular invasion, where systemic therapies become the standard of care.

Pitfalls to Avoid (and When to Get Help)

Navigating the management of intermediate-stage HCC requires careful, multidisciplinary coordination. Several common pitfalls can compromise patient outcomes.

  • Failing to refer for transplant evaluation: For any potentially eligible cirrhotic patient with a new HCC within Milan criteria, a prompt referral to a transplant center is crucial, even if other treatments are being considered.
  • Underestimating the risk of resection: Performing a liver resection in a patient with unappreciated portal hypertension can lead to post-operative liver decompensation and poor outcomes.
  • Inadequate post-treatment surveillance: HCC has a high propensity for recurrence. A lapse in scheduled follow-up imaging can allow a recurrence to grow beyond the point where effective salvage therapy is possible.
  • Choosing ablation for a poorly located tumor: Attempting percutaneous ablation on a 4 cm tumor adjacent to the gallbladder, a major vessel, or the diaphragm carries a high risk of incomplete treatment and complications.

If a patient shows signs of rapid tumor progression on surveillance, develops new vascular invasion, or experiences a decline in liver function, immediate escalation and discussion at a multidisciplinary tumor board is essential to re-evaluate the treatment plan.

Related ACR Topics and Tools

This article focuses on one specific clinical scenario. For a comprehensive overview of all variants and management strategies, or to explore tools for other clinical questions, the following resources are available.

Frequently Asked Questions

Why isn’t percutaneous ablation rated ‘Usually appropriate’ for a 4 cm HCC?

For tumors larger than 3 cm, it becomes technically challenging to achieve a complete cell kill with an adequate safety margin using thermal ablation (like radiofrequency or microwave). This leads to a significantly higher rate of local tumor recurrence compared to its effectiveness for smaller lesions. Therefore, for tumors in the 3-5 cm range, it is rated ‘May be appropriate’ and is often reserved for patients who are not candidates for resection or transplant.

What are the Milan criteria and how do they apply here?

The Milan criteria are a widely used set of guidelines to select patients with HCC for liver transplantation. They include having a single tumor 5 cm or less in diameter, or up to three separate tumors, none larger than 3 cm, with no evidence of gross vascular invasion or extrahepatic spread. A patient with a solitary 3-5 cm tumor fits squarely within these criteria, making them an ideal transplant candidate.

If a patient gets TACE as a bridge to transplant, how does that affect their MELD score?

Standard MELD scores are based on lab values reflecting liver function and do not account for cancer. To prioritize patients with HCC on the transplant list, those who meet criteria (like the Milan criteria) are granted MELD ‘exception points.’ These points ensure they have a chance at transplantation comparable to patients with non-cancerous end-stage liver disease. Successful TACE treatment does not remove these exception points.

Can a patient undergo both resection and then later, transplantation?

Yes, this is known as ‘salvage transplantation.’ A patient who is a good candidate for resection may undergo that procedure first. If the HCC recurs in the liver at a later time and is still within transplant criteria, they can then be listed for a salvage transplant. This approach is considered in select centers for patients with well-compensated liver disease.

What is the role of systemic therapy in this specific scenario?

For a solitary 3-5 cm HCC without vascular invasion or metastasis, systemic therapies (like tyrosine kinase inhibitors or immunotherapy) are rated ‘Usually not appropriate’ as a first-line treatment. The goal in this scenario is curative-intent locoregional or surgical therapy. Systemic therapy is reserved for patients who have advanced disease at presentation or whose disease progresses despite local treatments.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026